- $6.24m
- $5.01m
- 14
- 100
- 17
- 38
Annual income statement for Xeriant, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.39 | 11 | 6.47 | 1.9 | 1.37 |
| Operating Profit | -2.39 | -11 | -6.47 | -1.9 | -1.37 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2.7 | -15.9 | -7.1 | -3.1 | -1.65 |
| Net Income After Taxes | -2.7 | -15.9 | -7.1 | -3.1 | -1.65 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.49 | -13.3 | -7.07 | -3.07 | -1.63 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.49 | -13.3 | -7.07 | -3.07 | -1.63 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.01 | -0.039 | -0.007 | -0.007 | -0.003 |